Trial reports tumor shrinkage and some complete responses from amivantamab in treatment-resistant head and neck cancer
The facts
- The trial tested amivantamab in patients with recurrent and/or metastatic head and neck cancer whose disease had spread or returned after other treatments stopped working.
- The study was international, spanning 11 countries.
- Reports on the trial say tumors shrank in 42% of patients, or in more than a third of participants.
- In 15 patients, doctors reported complete disappearance of tumors after treatment with amivantamab.
- The trial included 102 patients.
- The patients in the trial had disease that had become resistant to both chemotherapy and immunotherapy, a group described by researchers as having limited remaining treatment options.
- Amivantamab was given as an injection rather than the intravenous-drip format used for many cancer medicines.
- The reports describe these findings as coming from a trial, meaning further study is still needed before the treatment's role in routine care is settled.
Context
Who was included in this trial?
The trial involved 102 patients with recurrent or metastatic head and neck cancer whose disease had spread or returned and was no longer responding to standard treatment, including chemotherapy and immunotherapy Independent,il Giornale.it,Metro,Irish Times.
What results were reported?
Across reports on the study, amivantamab was said to shrink tumors in 42% of patients, and doctors reported complete tumor disappearance in 15 patients Mirror,ITV Hub,Metro,Irish Times.
Why are these findings getting attention?
The results concern a patient group whose cancer had already stopped responding to existing treatments, so any evidence of tumor shrinkage or complete response could point to a new option where few remain; however, the evidence cited here comes from a clinical trial, so more research is needed Independent,Metro,Irish Times.
Common ground, and where they split
- Common ground
- Patients whose head and neck cancer had already resisted chemotherapy and immunotherapy have few remaining options, so reports of tumors shrinking in 42% of cases and disappearing entirely in 15 are meaningful even though the findings are still preliminary.
- Where Left and Right split
- Less a disagreement than a question of emphasis: the significance of a rare response in patients with limited options, versus the discipline of treating an encouraging trial signal as unproven until routine use is settled.
How left and right read it
What stands out here is that the trial focused on people with recurrent or metastatic head and neck cancer whose disease had already become resistant to both chemotherapy and immunotherapy, leaving them with limited remaining options. In that context, reports that tumors shrank in 42% of patients and disappeared completely in 15 cases are striking, even as the findings are still early and further study is needed before routine use is settled.
What stands out here is a concrete result in a hard case: among 102 patients whose cancer had already resisted both chemotherapy and immunotherapy, reports say tumors shrank in 42% of patients and disappeared entirely in 15 cases. Just as important, this remains a trial, so the encouraging signal should be taken seriously without pretending the treatment’s place in routine care is already settled.
The receipts — 54 sources
Other coverage (54)
A news briefing built to show both sides.
The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.